Response and Relapse in Patients With Schizophrenia Treated With Olanzapine, Risperidone, Quetiapine, or Haloperidol: 12-Month Follow-Up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) Study
J Clin Psychiatry 2005;66(8):1021-1030
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: The primary aim of this study was to
compare the effectiveness of 12 months' treatment with
olanzapine, risperidone, quetiapine, or haloperidol in preventing
relapse of schizophrenia. The study also examined other measures
of clinical effectiveness and tolerability.
Method: Outpatients with schizophrenia (ICD-10
or DSM-IV), who initiated or changed antipsychotic treatment,
entered this 3-year, naturalistic, prospective, observational
study between November 2000 and December 2001. At baseline,
subsets of patients were prescribed monotherapy with olanzapine
(N = 3222), risperidone (N = 1116), quetiapine (N = 189), or
haloperidol (N = 256). Patients remaining on monotherapy were
assessed using the Clinical Global Impression-Schizophrenia
scale. Relapse rate was determined from the responder subset.
Treatment patterns, patient perception of treatment compliance,
substance and alcohol intake patterns, and treatment tolerability
were recorded. Results are based on 12-month treatment data.
Results: Compared to haloperidol-treated
patients, olanzapine- and risperidone-treated patients had
approximately 3 to 4 times higher odds of response at 12 months
(p <= .001) and 6 times lower odds of relapse (p <= .001 for
olanzapine-treated patients).Among patients treated with atypical
antipsychotics, olanzapine- and risperidone-treated patients had
lower odds of relapse (although the difference was not
significant at p <= .001) and significantly higher odds of
response (p <= .001) compared to quetiapine-treated patients.
The tolerability profile generally favored the atypical
antipsychotics over haloperidol.
Conclusion: These interim results support
the findings of randomized controlled trials and verify that in
this naturalistic study, patients treated with olanzapine or
risperidone monotherapy were less likely to experience relapse
than patients who received haloperidol. The clinical
effectiveness and tolerability profile varied significantly
between the atypical antipsychotics.